LBI-HTA - Publications - Search - Horizon Scanning in Oncology: Results of the 29th Prioritisation – 4th quarter 2016.

Grössmann, N. and Wolf, S. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 29th Prioritisation – 4th quarter 2016.. HSO: 29th Prioritisation.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
228Kb
Abstract

For the 29th prioritisation (December 2016) the following two drugs for the treatment of breast cancer were selected for an "early assessment": Neratinib and Ribociclib. Further information about these drugs including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:HSO: 29th Prioritisation
Deposited on:10 Jan 2017 19:13
Last Modified:12 May 2017 14:02

Repository Staff Only: item control page